Dimensional Fund Advisors LP lowered its stake in Natus Medical Inc (NASDAQ:BABY) by 1.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,596,057 shares of the medical equipment provider’s stock after selling 17,465 shares during the quarter. Dimensional Fund Advisors LP owned about 4.73% of Natus Medical worth $54,314,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Paloma Partners Management Co acquired a new position in Natus Medical in the third quarter valued at about $218,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Natus Medical by 51.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,495 shares of the medical equipment provider’s stock valued at $85,000 after buying an additional 845 shares during the last quarter. Vaughan Nelson Investment Management L.P. acquired a new position in Natus Medical in the fourth quarter valued at about $33,985,000. MetLife Investment Advisors LLC lifted its position in Natus Medical by 52.4% in the third quarter. MetLife Investment Advisors LLC now owns 23,094 shares of the medical equipment provider’s stock valued at $823,000 after buying an additional 7,937 shares during the last quarter. Finally, BlackRock Inc. lifted its position in Natus Medical by 3.5% in the fourth quarter. BlackRock Inc. now owns 5,191,158 shares of the medical equipment provider’s stock valued at $176,656,000 after buying an additional 177,465 shares during the last quarter. 99.22% of the stock is currently owned by institutional investors.
In other news, Director Robert A. Gunst sold 8,304 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $28.09, for a total transaction of $233,259.36. Following the transaction, the director now directly owns 32,392 shares in the company, valued at $909,891.28. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Robert A. Gunst sold 6,304 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $27.96, for a total transaction of $176,259.84. Following the transaction, the director now owns 32,392 shares in the company, valued at $905,680.32. The disclosure for this sale can be found here. Corporate insiders own 5.50% of the company’s stock.
Natus Medical (NASDAQ:BABY) last announced its quarterly earnings results on Wednesday, February 13th. The medical equipment provider reported $0.43 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.50 by ($0.07). The company had revenue of $141.00 million during the quarter, compared to analysts’ expectations of $135.80 million. Natus Medical had a negative net margin of 4.32% and a positive return on equity of 11.64%. The business’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.42 earnings per share. As a group, research analysts expect that Natus Medical Inc will post 1.25 earnings per share for the current fiscal year.
A number of research firms have commented on BABY. ValuEngine raised shares of Natus Medical from a “hold” rating to a “buy” rating in a research report on Thursday, January 10th. BidaskClub raised shares of Natus Medical from a “hold” rating to a “buy” rating in a research report on Thursday, January 24th. William Blair reissued a “market perform” rating on shares of Natus Medical in a research report on Saturday, January 12th. Finally, Zacks Investment Research raised shares of Natus Medical from a “sell” rating to a “hold” rating in a report on Tuesday, December 25th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $36.00.
Natus Medical Company Profile
Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Recommended Story: Federal Reserve
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.